Renaissance Technologies LLC Raises Position in BioAge Labs, Inc. $BIOA

Renaissance Technologies LLC lifted its position in BioAge Labs, Inc. (NASDAQ:BIOA) by 653.2% during the 1st quarter, HoldingsChannel reports. The institutional investor owned 138,588 shares of the company’s stock after acquiring an additional 120,188 shares during the period. Renaissance Technologies LLC’s holdings in BioAge Labs were worth $2,424,000 as of its most recent SEC filing.

A number of other institutional investors have also recently made changes to their positions in the company. Russell Investments Group Ltd. bought a new stake in shares of BioAge Labs during the third quarter valued at approximately $27,000. CWM LLC lifted its position in BioAge Labs by 39.9% in the 4th quarter. CWM LLC now owns 3,693 shares of the company’s stock valued at $49,000 after acquiring an additional 1,053 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its stake in BioAge Labs by 85.6% during the 2nd quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 12,955 shares of the company’s stock valued at $54,000 after purchasing an additional 5,976 shares during the last quarter. Walleye Capital LLC purchased a new stake in BioAge Labs during the 2nd quarter valued at $64,000. Finally, Bank of America Corp DE increased its holdings in shares of BioAge Labs by 46.3% in the 3rd quarter. Bank of America Corp DE now owns 11,119 shares of the company’s stock worth $65,000 after purchasing an additional 3,517 shares in the last quarter.

BioAge Labs Trading Down 2.3%

Shares of NASDAQ BIOA opened at $11.45 on Tuesday. BioAge Labs, Inc. has a 12-month low of $4.25 and a 12-month high of $25.95. The firm has a market capitalization of $525.55 million, a price-to-earnings ratio of -4.81 and a beta of 0.94. The firm has a 50 day moving average of $19.93 and a 200 day moving average of $19.11.

BioAge Labs (NASDAQ:BIOA) last issued its quarterly earnings data on Wednesday, August 5th. The company reported ($0.58) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.65) by $0.07. The firm had revenue of $2.45 million during the quarter. BioAge Labs had a negative net margin of 912.26% and a negative return on equity of 28.99%. Sell-side analysts predict that BioAge Labs, Inc. will post -2.57 EPS for the current year.

Analyst Ratings Changes

BIOA has been the subject of several recent analyst reports. Jefferies Financial Group set a $21.00 price target on BioAge Labs in a research note on Friday, July 31st. Needham & Company LLC reduced their price objective on BioAge Labs from $50.00 to $35.00 and set a “buy” rating for the company in a report on Friday, July 31st. Roth Capital reissued a “buy” rating and issued a $25.00 target price on shares of BioAge Labs in a research report on Friday, July 31st. Wall Street Zen cut shares of BioAge Labs from a “hold” rating to a “sell” rating in a research note on Sunday, May 17th. Finally, BTIG Research reaffirmed a “buy” rating and set a $40.00 price target on shares of BioAge Labs in a report on Monday, August 3rd. Six research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, BioAge Labs presently has a consensus rating of “Moderate Buy” and a consensus price target of $36.57.

About BioAge Labs

BioAge Labs (NASDAQ: BIOA) is a clinical-stage biotechnology company focused on discovering and developing therapies that address age-associated diseases. The company leverages its proprietary analytics platform to mine large-scale human biological data for insights into the molecular mechanisms of aging. By targeting fundamental aging pathways, BioAge aims to create interventions that extend healthspan and treat conditions that disproportionately affect older populations.

At the core of BioAge’s operations is its integrated drug discovery platform, which combines human omics datasets, machine learning algorithms and experimental validation to identify novel drug targets.